Human Genome Epidemiology Literature Finder
Records 1 - 7 (of 7 Records) |
Query Trace: Breast Neoplasms and RRM1[original query] |
---|
An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. The oncologist 2007 Jun 12 (6): 622-30. Rha Sun Young, Jeung Hei Cheul, Choi Yeon Ho, Yang Woo Ick, Yoo Jin Ho, Kim Byung Soo, Roh Jae Kyung, Chung Hyun Che |
Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis. Hepato-gastroenterology 0 59 (117): 1609-13. Kasuya Kazuhiko, Tsuchida Akihiko, Nagakawa Yuichi, Suzuki Yoshiaki, Suzuki Minako, Aoki Tatsuya, Abe Yuta, Shimazu Motohide, Itoi Takao, Sofuni Atsus |
Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Cancer 2012 Nov 118 (22): 5588-94. Ren Shengxiang, Chen Xiaoxia, Kuang Peng, Zheng Limou, Su Chunxia, Li Jiayu, Li Bing, Wang Yongshen, Liu Lu, Hu Qiong, Zhang Jie, Tang Liang, Li Xuefei, Zhou Caicun, Schmid-Bindert Gera |
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. European journal of cancer (Oxford, England : 1990) 2014 Mar 50 (4): 698-705. Lee Soo-Youn, Im Seock-Ah, Park Yeon Hee, Woo Sook Young, Kim Seonwoo, Choi Moon Ki, Chang Wonjin, Ahn Jin Seok, Im Young-Hyu |
Association of novel gene polymorphisms RRM1 -756T>C and -269 C>A with breast cancer. Journal of clinical laboratory analysis 2014 Jul 28 (4): 287-93. Chen Dar-Ren, Chuang Chun-Yi, Wu Buor-Chang, Yang Shun-Fa, Peng Yu-Hsien, Tsai Hsiu-Ti |
Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer. Cancer communications (London, England) 2019 Oct 39 (1): 57. Lin Shaoyan, Yue Jian, Guan Xiuwen, Yuan Peng, Wang Jiayu, Luo Yang, Fan Ying, Cai Ruigang, Li Qiao, Chen Shanshan, Zhang Pin, Li Qing, Ma Fei, Xu Bing |
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). ESMO open 2020 Dec 6 (1): 100019. Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes A A, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 29, 2024
- Content source: